Blog

NHS Northern Treatment Advisory Group seeks to deny access to Wakix® in error filled evidence summary.

Our Annual Conference, 7/8 Oct 2017 - Charting Our way Ahead - links to plans to be released at conference to help bring narcolepsy to the attention of many more sectors of government, medical professionals, the workplace, education, and so on. This is your opportunity to be in at the start of something new and inspiring.

July/August 2017 issue of PharmaTimes features an article on narcolepsy. Thanks to Trustee, Steve Jones, for approaching PharmaTimes & also the publication for taking an interest in Narcolepsy.

"PharmaTimes is the UK's leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.

Is Wakix® the new Xyrem® ?

I do not ask this because of any similarities between what these two medications can do for people with narcolepsy but for other, far more frustrating reasons. Like Xyrem®, Wakix® has orphan drug status, its effects are not well understood, it is perceived as expensive and NHS adoption is slow because it is relatively new, despite the relevant NICE guidelines.

On May 23rd, 2016, I wrote the following paragraph: